Our mixed-methods evaluation, when combined with the findings from the NHS process and clinical data analyses, found that the NHS LCD programme (now NHS T2D Path to Remission) provides a clinically effective and cost-effective programme to support weight loss and glycaemic control in adults with T2D. However, the evaluation also identified some areas for improvement in referral equity, uptake and completion, and fidelity of delivery, which have already informed the development of the programme and the decision to roll out nationally. The findings provide one of the first and largest evaluations of this intervention approach and demonstrate that real-world implementation results can align with those from the underpinning trials, although the ability to monitor long-term impact is now critical.
All study publications are listed in Box 2.